Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALADDIN: Leuprolide in Alzheimer's Disease
NCT00063310Phase 2Completed
- Sponsor
- Voyager Therapeutics
- Start
- Mar 2003
- Primary completion
- Feb 2006
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of leuprolide in Alzheimer's disease (AD) (3 arms), sponsored by Voyager Therapeutics. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 48 weeks and Clinical Global Impression at 48 weeks. Started Mar 2003; status: completed.
02
Drugs
leuprolide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00063310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063310.